Home » Stocks » SURF

Surface Oncology, Inc. (SURF)

Stock Price: $11.02 USD -0.88 (-7.39%)
Updated Jan 27, 2021 2:16 PM EST - Market open
Market Cap 484.05M
Revenue (ttm) 39.03M
Net Income (ttm) -23.97M
Shares Out 40.00M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $11.02
Previous Close $11.90
Change ($) -0.88
Change (%) -7.39%
Day's Open 11.31
Day's Range 10.70 - 11.65
Day's Volume 988,062
52-Week Range 1.44 - 13.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

These baby biotechs are itching to come out of their shells.

Other stocks mentioned: JNCE
Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...

Zacks Investment Research - 1 month ago

Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The Motley Fool - 1 month ago

Investors reacted negatively to a big licensing deal.

GlobeNewsWire - 1 month ago

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG

The Motley Fool - 1 month ago

Biotech investors had more than just vaccines to think about this year.

Other stocks mentioned: CRDF, FPRX, MRSN, TRIL
GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...

The Motley Fool - 2 months ago

One has a better chance to keep climbing than the other does.

Other stocks mentioned: REPL
The Motley Fool - 2 months ago

These three stocks are loaded with potential, but need to be watched carefully over the next few weeks.

Other stocks mentioned: BNTX, MRNA
GlobeNewsWire - 2 months ago

Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose - limiting toxicities

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor mi...

GlobeNewsWire - 2 months ago

SRF388 inhibit s hepatocellular carcinoma tumor growth as a single agent in a preclinical model

Zacks Investment Research - 2 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: GRBK, HRI, MATX, MBIN
GlobeNewsWire - 3 months ago

Crystal structure of IL-27 in complex with SRF388 demonstrates inhibition of downstream signaling events and provides basis to measure therapeutic inhibition of IL-27 Crystal structure of IL-2...

Zacks Investment Research - 3 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CSTL, DQ, HRI
The Motley Fool - 3 months ago

The small biotech could be preparing to sell to a big drugmaker.

Zacks Investment Research - 3 months ago

The small-cap stocks have outperformed their large-cap peers in the market's turnaround from the September turmoil.

Other stocks mentioned: HIBB, LAKE, LL, MRBK, NLS, NRIM
GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor Surface Oncology.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

Zacks Investment Research - 4 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: ALDX, FLGT, NIU, PRIM
Zacks Investment Research - 4 months ago

Surface Oncology (SURF) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tum...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

Forbes - 6 months ago

With the S&P 500 looking to hold on to positive year-to-date gains despite a recession, you may be wondering how long this rally can last.

Other stocks mentioned: CATO, PFBI, VICR, WWR
Benzinga - 8 months ago

Shares of micro-cap biopharma Surface Oncology Inc (NASDAQ: SURF) are advancing strongly Wednesday following an oncology partnership the company announced with Merck & Co.

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

Zacks Investment Research - 8 months ago

Surface Oncology Inc (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tu...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tu...

Zacks Investment Research - 10 months ago

Is (SURF) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 11 months ago

Is (SURF) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor Surface Oncology, Inc. (SURF).

GlobeNewsWire - 11 months ago

Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

GlobeNewsWire - 1 year ago

Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors

Zacks Investment Research - 1 year ago

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019.

GlobeNewsWire - 1 year ago

Company to provide additional updates at its inaugural R&D day on November 18th in New York Company to provide additional updates at its inaugural R&D day on November 18th in New York

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...

GlobeNewsWire - 1 year ago

Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience Chief medical officer at Parker Institute for Ca...

Zacks Investment Research - 1 year ago

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019.

Zacks Investment Research - 1 year ago

Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 1 year ago

Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019.

About SURF

Surface Oncology, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreeme... [Read more...]

Industry
Biotechnology
IPO Date
Apr 19, 2018
CEO
J. Jeffrey Goater
Employees
49
Stock Exchange
NASDAQ
Ticker Symbol
SURF
Full Company Profile

Financial Performance

In 2019, SURF's revenue was $15.36 million, a decrease of -74.15% compared to the previous year's $59.42 million. Losses were -$54.79 million, 730.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is 15.40, which is an increase of 39.75% from the latest price.

Price Target
$15.40
(39.75% upside)
Analyst Consensus: Strong Buy